scholarly journals Liver Metastasis of Urothelial Carcinoma with Hepatoid Features: An Unusual Morphological Finding

2017 ◽  
Vol 37 (2) ◽  
pp. 801-804 ◽  
Author(s):  
PAUL FRIEDMAN ◽  
JIN-PING LAI
Keyword(s):  
Liver Metastasis ◽  
Urothelial Carcinoma ◽  
Morphological Finding

scholarly journals Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis

2021 ◽  
Author(s):  
Takafumi Yanagisawa ◽  
Keiichiro Mori ◽  
Satoshi Katayama ◽  
Hadi Mostafaei ◽  
Fahad Quhal ◽  
...  
Keyword(s):  
Systematic Review ◽  
Liver Metastasis ◽  
Urothelial Carcinoma ◽  
Clinical Characteristics ◽  
Clinical Decision Making ◽  
Group Performance ◽  
Meta Analysis ◽  
Eastern Cooperative Oncology Group ◽  
Primary Data ◽  
Metastatic Urothelial Carcinoma

AbstractPembrolizumab is the standard for the first and second lines in treating metastatic urothelial carcinoma (UC). This systematic review and meta-analysis aimed to assess the value of pretreatment clinical characteristics and hematologic biomarkers for prognosticating response to pembrolizumab in patients with metastatic UC. PUBMED®, Web of Science™, and Scopus® databases were searched for articles published before May 2021 according to the PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analyses) statement. Studies were deemed eligible if they evaluated overall survival (OS) in patients with metastatic urothelial carcinoma treated with pembrolizumab and pretreatment clinical characteristics or laboratory examination. Overall, 13 studies comprising 1311 patients were eligible for the meta-analysis. Several pretreatment patients’ demographics and hematologic biomarkers were significantly associated with worse OS as follows: Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ≥ 2 (Pooled hazard ratio [HR]: 3.24, 95% confidence interval [CI] 2.57–4.09), presence of visceral metastasis (Pooled HR: 1.84, 95% CI 1.42–2.38), presence of liver metastasis (Pooled HR: 4.23, 95% CI 2.18–8.20), higher neutrophil–lymphocyte ratio (NLR) (Pooled HR: 1.29, 95% CI 1.07–1.55) and, higher c-reactive protein (CRP) (Pooled HR: 2.49, 95% CI 1.52–4.07). Metastatic UC patients with poor PS, liver metastasis, higher pretreatment NLR and/or CRP have a worse survival despite pembrolizumab treatment. These findings might help to guide the prognostic tools for clinical decision-making; however, they should be interpreted carefully, owing to limitations regarding the retrospective nature of primary data.

Clinical features and outcomes of tumor lysis syndrome in patients with genitourinary cancers.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 533-533
Author(s):  
Jue Wang ◽  
Bryan Leung
Keyword(s):  
Prostate Cancer ◽  
Renal Cell Carcinoma ◽  
Liver Metastasis ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Features ◽  
Renal Cell ◽  
Tumor Lysis Syndrome ◽  
Tumor Lysis ◽  
Genitourinary Cancers

533 Background: Genitourinary (GU) cancers account about 20% of all human cancer in the United States. Tumor lysis syndrome (TLS) is an oncologic emergency with few treatment options. While TLS has been extensively documented in patients with hematological malignancies, it is rarely described in patients with GU cancers. The objective of this study was to investigate the clinical characteristics and outcomes of TLS, a rare but life-threatening complication in GU cancers. Methods: Systematic review of the literature and pooled analysis of published cases of TLS in GU cancers. Results: A total of 180 patients with TLS in solid tumor were included in our study. The median age was 57 years (8-94). Male: female ratio was 1.7. The most common sites were gastrointestinal (29%); followed by genitourinary (22%); lung (16%); melanoma (11%), breast cancer (8.3%). Liver metastasis was documented in 70% of study subjects. TLS occurred as a consequence of cancer therapy in 68% of subjects; and spontaneously in 32% of subjects. Older age and liver metastasis predict high mortality. The clinical features, treatment and outcomes of TLS in 40 cases of GU cancers including testicular germ cell tumor (TGCT) (n=14), renal cell carcinoma (n=10), prostate cancer (n=15), penile cancer (n=1) and urothelial carcinoma (n=3) were compared. The mortality rate of TLS were 50% in TGCT, 70% in renal cell carcinoma, 64% in prostate cancer 67% in urothelial carcinoma. Conclusions: TLS in GU cancers is associated with very high mortality. TLS should be considered on the differential diagnosis, when evaluating renal failure and electrolyte derangement in patients with metastatic GU cancers with liver metastases. The clinical features and outcomes of TLS in genitourinary cancers. [Table: see text]

EGFR induced-tyrosine phosphorylation of ZO-1 may regulate the liver metastasis of colorecial cancer

2001 ◽  
Vol 120 (5) ◽  
pp. A168-A168
Author(s):  
T KAIHARA ◽  
T KUSAKA ◽  
H KAWAMATA ◽  
Y ODA ◽  
J IMURA ◽  
...  
Keyword(s):  
Liver Metastasis ◽  
Tyrosine Phosphorylation

403: Desmoplasia is an Independent Prognostic Indicator in Urothelial Carcinoma of the Upper Urinary Tract

2007 ◽  
Vol 177 (4S) ◽  
pp. 134-134
Author(s):  
Richard E. Zigeuner ◽  
Thomas Chromecki ◽  
Sebastian Leibl ◽  
Peter Rehak ◽  
Cord Langner
Keyword(s):  
Urinary Tract ◽  
Urothelial Carcinoma ◽  
Prognostic Indicator ◽  
Upper Urinary Tract

602: COX-2 Inhibition: A Mechanism for Increasing the Efficacy of BCG Immunotherapy for Urothelial Carcinoma

2005 ◽  
Vol 173 (4S) ◽  
pp. 164-165
Author(s):  
Simon Dovedi ◽  
John A. Kirby ◽  
Helen Atkins ◽  
Barry R. Davies ◽  
John D. Kelly
Keyword(s):  
Urothelial Carcinoma ◽  
Bcg Immunotherapy ◽  
Cox 2

1093: Tumor Necrosis as Prognostic Indicator in Urothelial Carcinoma of the Upper Urinary Tract

2006 ◽  
Vol 175 (4S) ◽  
pp. 351-352
Author(s):  
Richard E. Zigeuner ◽  
Georg Hutterer ◽  
Thomas Chromecki ◽  
Sebastian Leibl ◽  
Peter Rehak ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Urothelial Carcinoma ◽  
Tumor Necrosis ◽  
Prognostic Indicator ◽  
Upper Urinary Tract

405: Alpha-Methylacyl-CoA Racemase (AMACR/P504S) Protein Expression in Urothelial Carcinoma of the Upper Urinary Tract Correlates with Tumour Progression

2006 ◽  
Vol 175 (4S) ◽  
pp. 132-132
Author(s):  
Richard E. Zigeuner ◽  
Sebastian Leibl ◽  
Georg Hutterer ◽  
Thomas Chromecki ◽  
Peter Rehak ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Protein Expression ◽  
Urothelial Carcinoma ◽  
Tumour Progression ◽  
Upper Urinary Tract

642: Novel Prediction of Chemosensitivity in Urothelial Carcinoma by Transcriptional Profiling

2006 ◽  
Vol 175 (4S) ◽  
pp. 206-207
Author(s):  
Dmytro M. Havaleshko ◽  
Hyungjun Cho ◽  
Mark Conaway ◽  
Jae K. Lee ◽  
Dan Theodorescu
Keyword(s):  
Urothelial Carcinoma ◽  
Transcriptional Profiling
Sign in / Sign up

Export Citation Format

Share Document